1Simon DD,Chantal P,David R.Williamson Brain natriureticpeptide in the management of heart failure:the versatile neuro-hormone[J].Chest Feb,2004,125:652-668.
2lemens LE,Almirez RG,Baudouin KA,et al.Pharmacokinetics andbiological actions of subcutaneously administered human brain natri-uretic peptide[J].J Pharmacol Exp Ther,1998,287(1):67-71.
3Moson LK,Harrison A,Krishnaswamy P,et al.Utility of a ra-pid B-natriuretic pepetide assay in differentiating congestiveheart failure from lung disease in patients presenting with dyap-nea[J].J Am Coll Cardiol,2002,39:202-209.
4Dao Q,Krishnaswamy P,Kazanegra R,et al.Utility of B-type na-triuretic peptide in the diagnosis of congestive heart failure in an-urgent-care setting[J].J Am Coll Cardiol,2001,37:379-385.
同被引文献8
1Fuat A, Murphy JJ, Hungin AP, et al. The diagnostic accuracy and utility of a B-type natriurethe peptide test in a community population of patients with suspected heart failure [ J ]. Bri J Gen Pract, 2006, 56(526) :327 -33.
2Betli I,Caotelli G,Barchielli A,et al. The Role of N-terminal Pro - brains natfiuretic peptidc and echocardiography for screening asymp- tomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study [ J ]. J Cardic Failure, 2009,15 (5) :377 -84.
3lshii A, Junichi A, Rinsho Bi. Clinical utility of NT-proBNP, a new biomarker of cardiac function and heart failure [ J ]. Jpn J Clin Pathol,2008,56(4) :316 -21.
